Physician profile
Timothy B Light
NPI 1255743043
$1,845.04
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $186 · 2021: $256 · 2022: $466 · 2023: $121 · 2024: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $272.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $230.79 | 2019-2023 | |
| Glaxosmithkline, LLC. | $209.50 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $208.51 | 2019-2024 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $120.31 | 2022 | |
| Amgen INC. | $96.85 | 2019-2024 | Repatha |
| Lilly USA, LLC | $89.64 | 2019-2022 | |
| Novo Nordisk INC | $80.82 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $79.69 | 2019-2022 | |
| Exact Sciences Corporation | $72.59 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $61.02 | 2019-2023 | Myrbetriq |
| Abbott Laboratories | $60.49 | 2021-2024 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $59.88 | 2019-2023 | Vaxelis, Gardasil 9, M-M-R II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.91 | 2019 | |
| Allergan, INC. | $46.75 | 2019-2020 | |
| Pfizer INC. | $43.14 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $39.13 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.46 | 2019-2021 | |
| Dexcom, INC. | $31.75 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $30.74 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $29.49 | 2019 | |
| Amarin Pharma, INC. | $28.10 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $21.94 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $18.49 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.06 | 2022 | |
| Cequr Corporation | $15.41 | 2024 | Cequr Simplicity |
| Grifols USA, LLC | $12.87 | 2020 | |
| Medtronic, INC. | $12.83 | 2022 | |
| Cranial Technologies, INC | $12.25 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.89 | 2021 | |
| Sanofi Pasteur INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Light listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.